Conducting clinical research studies with
Call to participate

Alzheimer’s Disease Registry

RAmP Registry for Amyloid Positive Patients

Avid Radiopharmaceuticals (Avid) is sponsoring a research registry to identity patients who have a positive PET scan result for amyloid protein in the brain.

The goal of the registry is to identify patients who may be eligible for Eli Lilly and Company (Lilly) clinical trials for Alzheimer’s Disease. Participants who are potentially eligible for Lilly research opportunities will be matched with Clinical Trial investigators in their geographical area.

Avid will use the results of the registry to find out whether such registries are beneficial for enrollment of Alzheimer’s Disease clinical trials.

In order to participate, you must meet the following criteria:

  • Be at least 50 years of age
  • Have cognitive impairment with diagnosed or suspected Alzheimer’s disease
  • Have a positive amyloid PET scan. If you have not had a PET scan in the past, you must be willing to complete a scan as part of the RAmP Registry Addendum
  • Have a study partner (Informant) who is willing to participate with you.
  • Be willing to be contacted for possible participation in Eli Lilly and Company (Lilly) clinical trials
  • Provide written informed consent

Contact Coastal Connecticut Research to learn more at (860) 443-4567 or to request a brochure.  Study team includes Dr. Laurence Radin, Andrea Stewart APRN, Diane Palmer RN, and  Jeannine Elliott RN.